Myelodysplastic syndrome associated with multiple autoimmune disorders.
The association between myelodysplastic syndromes (MDS) and autoimmune manifestations is not uncommon. As a rule, autoimmune abnormalities follow the diagnosis of MDS. We describe here a patient with MDS who developed a striking spectrum of diverse autoimmune disorders, including dermatitis, polyarthritis, and vasculitis, which preceded the clinical appearance of MDS.
Farmakis
Dimitrios
D
First Department of Internal Medicine, Laiko General Hospital, University of Athens Medical School, Greece. dfarm1@panafonet.gr
Polymeropoulos
Evaggelos
E
Polonifi
Aikaterini
A
Deftereos
Spyros
S
Giakoumi
Xanthoula
X
Floudas
Harris
H
Grapsa
Antonia
A
Aessopos
Athanasios
A
D000368:Aged; D000369:Aged, 80 and over; D001168:Arthritis / Q000150:complications / Q000175:diagnosis; D001327:Autoimmune Diseases / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D001803:Blood Transfusion / Q000379:methods; D003131:Combined Modality Therapy; D003872:Dermatitis / Q000150:complications / Q000175:diagnosis; D004359:Drug Therapy, Combination; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D000069585:Filgrastim; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D011994:Recombinant Proteins; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014657:Vasculitis / Q000150:complications / Q000175:diagnosis
D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068817:Epoetin Alfa; D000069585:Filgrastim; D008775:Methylprednisolone